GPCR241220C40000
- 1.10
- +0.40+57.14%
Structure Therapeutics Newsroom
Structure Therapeutics Inc. (GPCR): Among the NASDAQ Stocks With Biggest Upside Potential According to Analysts
The "Diet Duo" leads a sharp decline in pharmaceutical stocks, as Trump's new health secretary opposes vaccines and weight loss drugs.
Kennedy, known as the "anti-vaccine pioneer," strongly opposes GLP-1 drugs, believing they are the wrong approach to addressing the obesity crisis. On Friday, the stock prices of the "weight loss giants" eli lilly and co and novo-nordisk a/s fell by 4.93% and 3.4%, respectively, and other companies dedicated to developing weight loss drugs also suffered heavy losses.
Morgan Stanley Maintains Structure Therapeutics(GPCR.US) With Buy Rating, Maintains Target Price $118
Structure Therapeutics to Participate in the Jefferies London Healthcare Conference
Jefferies Maintains Structure Therapeutics(GPCR.US) With Buy Rating, Maintains Target Price $79
Structure Therapeutics Reports Strong Q3 2024 Results
Structure Therapeutics | 10-Q: Q3 2024 Earnings Report
Express News | Structure Therapeutics Inc - Topline Data From Access and Access II Studies Expected Q4 2025
Structure Therapeutics Q3 EPS $(0.20), Inline
Structure Therapeutics | 8-K: Structure Therapeutics Reports Third Quarter 2024 Financial Results and Recent Highlights First patients dosed in Phase 2b ACCESS study of GSBR-1290 for obesity
Express News | Structure Therapeutics Inc: Expects Current Cash, Cash Equivalents & Short-Term Investments to Fund Operations Through at Least 2027
Express News | Structure Therapeutics Reports Third Quarter 2024 Financial Results and Recent Highlights
Express News | Structure Therapeutics Inc. Q3 Net Income USD -33.977 Million
Express News | Structure Therapeutics Inc. Q3 Income From Operations USD -45.836 Million
Express News | Structure Therapeutics Announces First Patients Dosed in Phase 2B Access Clinical Study Evaluating Oral Small Molecule GLP-1 Receptor Agonist, Gsbr-1290, for Obesity
Piper Sandler Maintains Structure Therapeutics(GPCR.US) With Buy Rating, Maintains Target Price $93
Piper Sandler Remains a Buy on Structure Therapeutics, Inc. Sponsored ADR (GPCR)
Structure Therapeutics Announces Multiple Upcoming Presentations at ObesityWeek 2024
Top Small-cap Stock Picks From Morgan Stanley Following the Group's Upgrade to Neutral
BMO Capital Maintains Structure Therapeutics(GPCR.US) With Buy Rating, Maintains Target Price $100